- Home
- RAND vs IGC Comparison
RAND vs IGC Comparison
Compare RAND & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- IGC
- Stock Information
- Founded
- RAND 1969
- IGC 2005
- Country
- RAND United States
- IGC United States
- Employees
- RAND N/A
- IGC N/A
- Industry
- RAND Finance: Consumer Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- IGC Health Care
- Exchange
- RAND Nasdaq
- IGC Nasdaq
- Market Cap
- RAND 41.3M
- IGC 33.8M
- IPO Year
- RAND N/A
- IGC N/A
- Fundamental
- Price
- RAND $14.00
- IGC $0.34
- Analyst Decision
- RAND
- IGC Strong Buy
- Analyst Count
- RAND 0
- IGC 2
- Target Price
- RAND N/A
- IGC $4.00
- AVG Volume (30 Days)
- RAND 3.0K
- IGC 928.5K
- Earning Date
- RAND 11-07-2025
- IGC 11-17-2025
- Dividend Yield
- RAND 11.94%
- IGC N/A
- EPS Growth
- RAND N/A
- IGC N/A
- EPS
- RAND N/A
- IGC N/A
- Revenue
- RAND $7,327,287.00
- IGC $1,106,000.00
- Revenue This Year
- RAND N/A
- IGC $3.54
- Revenue Next Year
- RAND N/A
- IGC $15.12
- P/E Ratio
- RAND N/A
- IGC N/A
- Revenue Growth
- RAND N/A
- IGC N/A
- 52 Week Low
- RAND $13.40
- IGC $0.25
- 52 Week High
- RAND $31.89
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- RAND 50.04
- IGC 30.99
- Support Level
- RAND $13.76
- IGC $0.35
- Resistance Level
- RAND $14.00
- IGC $0.37
- Average True Range (ATR)
- RAND 0.23
- IGC 0.03
- MACD
- RAND 0.06
- IGC -0.01
- Stochastic Oscillator
- RAND 100.00
- IGC 3.70
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.